Literature DB >> 17952395

Large intra- and inter-individual variability of genes expression levels limits potential predictive value of molecular diagnosis of dysplasia in Barrett's esophagus.

Ewa E Hennig1, Michal Mikula, Janina Orlowska, Dorota Jarosz, Andrzej Bielasik, Jaroslaw Regula, Jerzy Ostrowski.   

Abstract

Barrett's esophagus represents a well-defined precursor lesion of esophageal adenocarcinoma, although only a subset of patients with these lesions advances to invasive cancer. Currently, reliable markers predicting neoplastic progression in Barrett's esophagus are lacking. The only clinically useful risk factor is the presence of dysplasia in Barrett's epithelium, but its use as a prognostic marker of disease progression has several significant limitations. Thus, identification of biomarkers of potential prognostic value in dysplasia development in Barrett's esophagus is highly important. The aim of the study was to determine if expression levels of selected genes support histologic diagnosis of dysplastic changes in Barrett's esophagus. Upon rigorous sampling and independent histopathologic examination of endoscopic specimens by two experienced gastrointestinal pathologists, 56 patients with Barrett's esophagus (16 negative for dysplasia, 15 with indefinite, 21 with low-grade, and 4 with high-grade dysplasia) were selected for molecular analysis. The relative mRNA levels of ten selected genes were estimated by quantitative real-time polymerase chain reaction (PCR) analysis. Although expression of nine genes showed trends toward down- or upregulation during progression from Barrett's esophagus without dysplasia to Barrett's esophagus with high-grade dysplasia, only a decrease in S100A2 mRNA levels was statistically significant (P<0.05). However, there was considerable variation among individuals and significant overlapping of ranges. Furthermore, detailed, comparative analysis of serial samples from Barrett's mucosa and normal squamous epithelium shows large intra-individual variability of gene expression levels. In conclusion, expression of this set of ten genes cannot be used as a molecular marker aiding histological examination of dysplasia in Barrett's esophagus. Significant inter- and intra-patient variations of gene expression levels makes use of the selected genes impractical.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17952395     DOI: 10.1007/s00109-007-0271-5

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  35 in total

Review 1.  The diagnosis of dysplasia and malignancy in Barrett's oesophagus.

Authors:  K Geboes; P Van Eyken
Journal:  Histopathology       Date:  2000-08       Impact factor: 5.087

2.  Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure.

Authors:  V N Shirvani; R Ouatu-Lascar; B S Kaur; M B Omary; G Triadafilopoulos
Journal:  Gastroenterology       Date:  2000-03       Impact factor: 22.682

3.  CDC2/CDK1 expression in esophageal adenocarcinoma and precursor lesions serves as a diagnostic and cancer progression marker and potential novel drug target.

Authors:  Donna E Hansel; Surajit Dhara; RuChih C Huang; Raheela Ashfaq; Mari Deasel; Yutaka Shimada; Harold S Bernstein; John Harmon; Malcolm Brock; Arlene Forastiere; M Kay Washington; Anirban Maitra; Elizabeth Montgomery
Journal:  Am J Surg Pathol       Date:  2005-03       Impact factor: 6.394

4.  Decreased expression of SPRR3 in Chinese human oesophageal cancer.

Authors:  B S Chen; M R Wang; Y Cai; X Xu; Z X Xu; Y L Han; M Wu
Journal:  Carcinogenesis       Date:  2000-12       Impact factor: 4.944

5.  The Vienna classification of gastrointestinal epithelial neoplasia.

Authors:  R J Schlemper; R H Riddell; Y Kato; F Borchard; H S Cooper; S M Dawsey; M F Dixon; C M Fenoglio-Preiser; J F Fléjou; K Geboes; T Hattori; T Hirota; M Itabashi; M Iwafuchi; A Iwashita; Y I Kim; T Kirchner; M Klimpfinger; M Koike; G Y Lauwers; K J Lewin; G Oberhuber; F Offner; A B Price; C A Rubio; M Shimizu; T Shimoda; P Sipponen; E Solcia; M Stolte; H Watanabe; H Yamabe
Journal:  Gut       Date:  2000-08       Impact factor: 23.059

6.  Quantitative, tissue-specific analysis of cyclooxygenase gene expression in the pathogenesis of Barrett's adenocarcinoma.

Authors:  Hidekazu Kuramochi; Daniel Vallböhmer; Kazumi Uchida; Sylke Schneider; Nahid Hamoui; Daisuke Shimizu; Parakrama T Chandrasoma; Tom R DeMeester; Kathleen D Danenberg; Peter V Danenberg; Jeffrey H Peters
Journal:  J Gastrointest Surg       Date:  2004-12       Impact factor: 3.452

7.  Survivin, a potential biomarker in the development of Barrett's adenocarcinoma.

Authors:  Daniel Vallböhmer; Jeffrey H Peters; Daniel Oh; Hidekazu Kuramochi; Daisuke Shimizu; Steven R Demeester; Jeffrey A Hagen; Parakrama T Chandrasoma; Kathleen D Danenberg; Tom R DeMeester; Peter Danenberg
Journal:  Surgery       Date:  2005-10       Impact factor: 3.982

8.  Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation.

Authors:  E Montgomery; M P Bronner; J R Goldblum; J K Greenson; M M Haber; J Hart; L W Lamps; G Y Lauwers; A J Lazenby; D N Lewin; M E Robert; A Y Toledano; Y Shyr; K Washington
Journal:  Hum Pathol       Date:  2001-04       Impact factor: 3.466

Review 9.  Barrett's esophagus and Barrett's-related dysplasia.

Authors:  John R Goldblum
Journal:  Mod Pathol       Date:  2003-04       Impact factor: 7.842

10.  Expression of apoptosis-related proteins in Barrett's metaplasia-dysplasia-carcinoma sequence: a switch to a more resistant phenotype.

Authors:  C J van der Woude; P L M Jansen; A T G M Tiebosch; A Beuving; M Homan; J H Kleibeuker; H Moshage
Journal:  Hum Pathol       Date:  2002-07       Impact factor: 3.466

View more
  4 in total

Review 1.  American Gastroenterological Association technical review on the management of Barrett's esophagus.

Authors:  Stuart J Spechler; Prateek Sharma; Rhonda F Souza; John M Inadomi; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2011-03       Impact factor: 22.682

2.  MicroRNA expression profiling in human Barrett's carcinogenesis.

Authors:  Matteo Fassan; Stefano Volinia; Jeff Palatini; Marco Pizzi; Raffaele Baffa; Marina De Bernard; Giorgio Battaglia; Paola Parente; Carlo M Croce; Giovanni Zaninotto; Ermanno Ancona; Massimo Rugge
Journal:  Int J Cancer       Date:  2011-03-11       Impact factor: 7.396

3.  Biomarkers in Barrett's Esophagus.

Authors:  Rhonda F Souza
Journal:  Tech Gastrointest Endosc       Date:  2010-04

4.  Whole genome expression array profiling highlights differences in mucosal defense genes in Barrett's esophagus and esophageal adenocarcinoma.

Authors:  Derek J Nancarrow; Andrew D Clouston; B Mark Smithers; David C Gotley; Paul A Drew; David I Watson; Sonika Tyagi; Nicholas K Hayward; David C Whiteman
Journal:  PLoS One       Date:  2011-07-28       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.